Previous 10 | Next 10 |
home / stock / casbf / casbf news
Adenoviruses have long been used as tools in molecular biology. The first step in this process is to engineer the viral DNA that you need and make a lot of it. It's a fundamentally different process than the mRNA vaccines, with its own features (good and bad). For further de...
CanSino Biologics (CASBF) says the company’s advancing the phase III clinical trial for its experimental COVID-19 vaccine after meeting the pre-specified primary safety and efficacy criteria at the interim analysis with no serious adverse events.According to Global Times, the comp...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
On Wednesday, China's National Medical Products Administration granted the conditional marketing approval for the COVID-19 vaccine candidate developed by Beijing Biological Products Institute and Sinopharm Group (SHTDF).Based mainly on trials conducted in the United Arab Emirates, t...
The UK authorities have approved Oxford/AstraZeneca’s adenovirus vector vaccine for distribution there. Of special interest is the intent to give as many people as possible a first shot, without holding back supplies for the second round. This is simultaneously the correct decision...
Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....
It's been a while since I went through the whole vaccine landscape (I've been putting it off!), but there's a lot to catch up on. I'm going to incorporate some slightly reworked material from my July post in the introduction to each vaccine class, for reference, but everything on the candida...
One of my investments is in a small COVID vaccine company, Heat Biologics ( HTBX ), and I generally route for the little guy. So I don't particularly like writing an article that has a number of facts and reasons why probably none of the remaining small players are going to become major player...
By ALT Perspective After suffering a bruising the previous week, Chinese equities staged a rebound. The representative Chinese equity index ETFs ( CQQQ )( FXI )( MCHI ) rallied 2.18 percent to 2.73 percent while their U.S. counterparts ( SPY )( DIA )( QQQ ) had a mixed performance, posti...
LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...